@article{1b83ebaa8d5d4df0a64b0991611b6ec3,
title = "Transcriptional signatures associated with rubella virus-specific humoral immunity after a third dose of MMR vaccine in women of childbearing age",
abstract = "Multiple factors linked to host genetics/inherent biology play a role in interindividual variability in immune response outcomes after rubella vaccination. In order to identify these factors, we conducted a study of rubella-specific humoral immunity before (Baseline) and after (Day 28) a third dose of MMR-II vaccine in a cohort of 109 women of childbearing age. We performed mRNA-Seq profiling of PBMCs after rubella virus in vitro stimulation to delineate genes associated with post-vaccination rubella humoral immunity and to define genes mediating the association between prior immune response status (high or low antibody) and subsequent immune response outcome. Our study identified novel genes that mediated the association between prior immune response and neutralizing antibody titer after a third MMR vaccine dose. These genes included the following: CDC34; CSNK1D; APOBEC3F; RAD18; AAAS; SLC37A1; FAS; and JAK2. The encoded proteins are involved in innate antiviral response, IFN/cytokine signaling, B cell repertoire generation, the clonal selection of B lymphocytes in germinal centers, and somatic hypermutation/antibody affinity maturation to promote optimal antigen-specific B cell immune function. These data advance our understanding of how subjects{\textquoteright} prior immune status and/or genetic propensity to respond to rubella/MMR vaccination ultimately affects innate immunity and humoral immune outcomes after vaccination.",
keywords = "RNA, genetic markers, immunity, humoral, rubella, rubella vaccine, transcriptome",
author = "Haralambieva, {Iana H.} and Eberhard, {Katherine G.} and Ovsyannikova, {Inna G.} and Grill, {Diane E.} and Schaid, {Daniel J.} and Kennedy, {Richard B.} and Poland, {Gregory A.}",
note = "Funding Information: Dr. Poland is a paid scientific advisor for Johnson & Johnson/Janssen Global Services LLC. Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Kentucky Bioprocessing, Bavarian Nordic, AstraZeneca, Exelixis, Regeneron, Vyrad, Moderna, and Genevant Sciences, Inc. Drs. Poland and Ovsyannikova hold patents related to vaccinia and measles peptide vaccines. Dr. Kennedy holds a patent related to vaccinia peptide vaccines. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. Funding Information: We thank Caroline L. Vitse for her valuable editorial assistance in preparing this manuscript. We thank Krista Goergen (Department of Health Sciences Research, Mayo Clinic) for her help in data analyses. Research reported in this review was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R37AI048793 and R01AI033144. The research of DJ Schaid was supported by the U.S. Public Health Service, National Institutes of Health, contract grant number GM065450. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: We thank Caroline L. Vitse for her valuable editorial assistance in preparing this manuscript. We thank Krista Goergen (Department of Health Sciences Research, Mayo Clinic) for her help in data analyses. Research reported in this review was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R37AI048793 and R01AI033144. The research of DJ Schaid was supported by the U.S. Public Health Service, National Institutes of Health, contract grant number GM065450. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2021 Wiley-VCH GmbH",
year = "2021",
month = jul,
doi = "10.1002/eji.202049054",
language = "English (US)",
volume = "51",
pages = "1824--1838",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "7",
}